GlassScriptPhysician profile
Nicole Cleveland
NPI 1639380207
$5,848.58
in general payments reported to CMS, 2019-2025
43 companies · $1,156 in 2025
The $1,156 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $663 · 2020: $202 · 2021: $653 · 2022: $900 · 2023: $1,399 · 2024: $875 · 2025: $1,156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,323 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,322.78 |
| Education | $106.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $771.79 | 2021-2025 | Reblozyl, Opdualag, Pomalyst |
| Exelixis INC. | $654.28 | 2020-2025 | Cabometyx |
| Janssen Biotech, INC. | $542.59 | 2019-2025 | Tecvayli, Darzalex, Talvey |
| Pfizer INC. | $356.24 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $301.51 | 2019-2025 | Opdivo |
| Merck Sharp & Dohme LLC | $300.26 | 2019-2025 | Keytruda |
| Astrazeneca Pharmaceuticals LP | $246.27 | 2022-2025 | Enhertu, Onglyza, Imfinzi |
| Gilead Sciences, INC. | $238.49 | 2021-2025 | Trodelvy |
| Astellas Pharma US INC | $234.18 | 2019-2025 | Vyloy, Xtandi |
| Genzyme Corporation | $189.93 | 2019-2023 | |
| Daiichi Sankyo INC. | $159.20 | 2023-2025 | Enhertu |
| Tersera Therapeutics LLC | $146.54 | 2023-2025 | Zoladex |
| Genentech USA, INC. | $144.46 | 2019-2022 | |
| Abbvie INC. | $138.54 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $132.93 | 2019-2022 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Deciphera Pharmaceuticals INC. | $107.14 | 2021-2025 | Qinlock, Tgct, Romvimza |
| Novartis Pharmaceuticals Corporation | $102.71 | 2021-2023 | |
| Pharmacyclics LLC, An Abbvie Company | $86.22 | 2021-2023 | Imbruvica |
| Seagen INC. | $79.96 | 2019-2023 | Padcev |
| Array Biopharma INC | $68.16 | 2020-2024 | Braftovi, Mektovi, Tukysa |
| Amgen INC. | $66.71 | 2019-2023 | Kyprolis |
| Beigene USA, INC. | $64.44 | 2021-2025 | Tevimbra |
| Recordati_rare_diseases_inc. | $63.62 | 2024-2025 | Sylvant |
| Glaxosmithkline, LLC. | $62.47 | 2022-2025 | Jemperli, Zejula |
| Octapharma USA, INC. | $54.81 | 2024-2025 | Octagam Immune Globulin (Human) |
| Kite Pharma, INC. | $54.53 | 2023-2025 | Yescarta |
| Jazz Pharmaceuticals INC. | $46.20 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $44.28 | 2021-2025 | |
| Mirati Therapeutics, INC. | $42.92 | 2023-2024 | Krazati |
| Eisai INC. | $42.55 | 2023-2024 | |
| Agios Pharmaceuticals, INC. | $40.13 | 2019-2020 | |
| Lilly USA, LLC | $38.98 | 2019-2022 | |
| Beone Medicines USA, INC. | $36.16 | 2025 | Tevimbra |
| Karyopharm Therapeutics INC. | $30.16 | 2021-2022 | |
| Secura Bio, INC. | $27.13 | 2022 | |
| Inari Medical, INC. | $21.35 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Springworks Therapeutics, INC. | $18.84 | 2024 | Ogsiveo |
| Fennec Pharmaceuticals, INC. | $17.45 | 2025 | Fyarro |
| Incyte Corporation | $15.88 | 2021 | |
| Azurity Pharmaceuticals, INC. | $15.01 | 2025 | Danziten |
| Acrotech Biopharma INC. | $15.00 | 2025 | Beleodaq |
| Epizyme, INC. | $14.77 | 2021 | |
| Blueprint Medicines Corporation | $13.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Cleveland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.